RESEARCH ARTICLE

Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations

Bajarang Vasant Kumbhar, Anubhaw Borogaon, Dulal Panda, Ambarish Kunwar

Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai-400076, Maharashtra, India

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* akunwar@iitb.ac.in

Abstract

Tubulin isotypes are found to play an important role in regulating microtubule dynamics. The isotype composition is also thought to contribute in the development of drug resistance as tubulin isotypes show differential binding affinities for various anti-cancer agents. Tubulin isotypes αβII, αβIII and αβIV show differential binding affinity for colchicine. However, the origin of differential binding affinity is not well understood at the molecular level. Here, we investigate the origin of differential binding affinity of a colchicine analogue N-deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA-colchicine) for human αβII, αβIII and αβIV isotypes, employing sequence analysis, homology modeling, molecular docking, molecular dynamics simulation and MM-GBSA binding free energy calculations. The sequence analysis study shows that the residue compositions are different in the colchicine binding pocket of αβII and αβIII, whereas no such difference is present in αβIV tubulin isotypes. Further, the molecular docking and molecular dynamics simulations results show that residue differences present at the colchicine binding pocket weaken the bonding interactions and the correct binding of DAMA-colchicine. Post molecular dynamics simulation analysis suggests that these residue variations affect the structure and dynamics of αβII and αβIII tubulin isotypes, which in turn affect the binding of DAMA-colchicine. Further, the binding free-energy calculation shows that αβIV tubulin isotype has the highest binding free-energy and αβIII has the lowest binding free-energy for DAMA-colchicine. The order of binding free-energy for DAMA-colchicine is αβIV ≈ αβII >> αβIII. Thus, our computational approaches provide an insight into the effect of residue variations on differential binding of αβII, αβIII and αβIV tubulin isotypes with DAMA-colchicine and may help to design new analogues with higher binding affinities for tubulin isotypes.
**Introduction**

Microtubules (MTs) play crucial roles in various important cellular functions such as cell division, cell motility, transport of vesicles, cell signaling, cell shaping and sensory transduction [1]. They are polymers of a heterodimeric protein, tubulin (Fig 1A). The α-tubulin and β-tubulin are encoded by multiple genes expressed in a tissue specific manner [2–5], such differential expression of tubulin isotype has functional significances [6–8]. Several β-tubulin isotypes are observed in mammals [2–4, 6, 9, 10]. In humans, eight isotypes of β-tubulin have been observed which are expressed differently in different tissues [4, 9, 11]. βI tubulin isotype is the most abundant type and is constitutively expressed, whereas βIII expression is restricted to neuronal tissues and testis. Cancerous cells deregulate tissue-specific expression of different isotypes; particularly the overexpression of βIII has been associated with aggressive drug resistant cancer cells [12–14]. Mutations in tubulin have also been associated with certain diseases e.g. Polymicrogyria (PMG), Malformation of Cortical Development (MCD) and Congenital Fibrosis of Extraocular Muscle type 3 (CFEOM3) [15–17].

In the present study, we investigate the binding affinity of different β-tubulin isotypes for colchicine analogue N-deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA-colchicine). Colchicine is the most widely studied anti-mitotic agent to understand the dynamics and function of microtubules. Colchicine is composed of three rings i.e. trimethoxy benzene ring (A ring), methoxytropone ring (C ring), both of which are attached to seven member B ring which has acetamido group at C7 position [18]. In DAMA-colchicine, acetamido group is replaced by...
mercaptoacetyl group at C7 position (Fig 1B). It has been shown that colchicine binds to tubulin with a very high affinity [19], and induces conformational changes in tubulin [20]. The X-ray crystallography study of αβ-tubulin (PDB ID: 1SA0, resolved at 3.58Å) shows that DAMA-colchicine binds at the interface of αβ-tubulin dimer [21]. α-tubulin and β-tubulin share 40% sequence similarity and each can be divided into the three functional domains; the N-terminal domain (1–205) containing the nucleotide binding region, intermediate domain (206–381), and C-terminal domain (382–450) (Fig 1A).

There have been various studies to understand the biochemical and biophysical properties of interaction of colchicine with tubulin [18, 22, 23], but its effect on various tubulin isotypes has not yet well been understood. The kinetic binding study of tubulin isotypes with colchicine showed that bovine β-tubulin isotype IV has the highest binding affinity, which is followed by β-tubulin isotype II and III respectively. The order of the binding affinities for colchicine is αβIV > αβII ≈ αβIII [24]. However, molecular reasons behind the differential binding affinity of these three tubulin isotypes for colchicine is not understood. Similarly, Banerjee et al. [25] studied the binding of desacetamidocolchicine (DAAC) with bovine tubulin isotypes αβII, αβIII and αβIV. DAAC is a colchicine analogue which lacks the acetamidogroup (NH-CO-CH) of B ring [25]. They found that the on-rate was slowest in case of αβIII isotype, and concluded that the colchicine binding domain on the αβIII isotype may differ from that of αβII and αβIV isotypes in a small region that might accommodate the B-ring of colchicine. They further concluded that the colchicine binding region is much less flexible in αβIII isotype. Hence, it is important to explore the origin of these differential binding affinities to develop effective analogues against drug-resistant tubulin isotypes.

In the present study, we employed sequence analysis, homology modeling, molecular docking, molecular dynamics simulations and binding free-energy calculations to investigate the differential binding affinity of the three human tubulin isotypes for colchicine analogue DAMA-colchicine.

**Materials and Methods**

**Sequence Analysis of Tubulin Isotype**

For multiple sequence analysis study of human β-tubulin isotypes, the sequences of βII, βIII and βIV were downloaded from the UniProt protein sequence database. The sequence of the template (Tubulin 1SA0) [21] was retrieved from the protein database. Since our template is from bovine, the sequences for bovine β-tubulin isotypes (βII, βIII and βIV) were also downloaded from the UniProt protein sequence database for comparison with human β-tubulin isotypes. The multiple sequence alignment of β-tubulin isotypes and template sequence were performed using online multiple sequence analysis tools of EMBL-EBI [26].

**Homology Modeling of Tubulin Isotypes**

To find out the mechanism of binding and the binding affinity of DAMA-colchicine with different human β-tubulin isotypes, we constructed 3D models of αβII, αβIII and αβIV isotypes using homology modeling, since it is known both experimentally [21] and computationally [27] that colchicine binds at the interface of α tubulin and β tubulin. A comparison of human β-tubulin isotypes βII (Uniprot ID: Q13885), βIII (Uniprot ID: Q13509) and βIV (Uniprot ID: P04350) with bovine tubulin isotypes βII (Uniprot ID: E1BJB1), βIII (Uniprot ID: Q2T950) and βIV (Uniprot ID: Q3ZBU7) using multiple sequence alignment, shows that they are identical i.e. 100% similar. We used crystal structure 1SA0.pdb [21] as a template for building 3D homology models of human αβ-tubulin isotypes. 1SA0.pdb is from bovine. Bovine βII tubulin (Uniprot ID: Q6B856) is identical in sequence to human βII tubulin (Uniprot ID: Q9BVA1).
This was the reason for choosing 1SA0.pdb as a template to build the 3D model of three tubulin isotypes from human.

We selected chains A and B, containing GTP and Mg\(^{2+}\) in \(\alpha\) tubulin, and GDP and Mg\(^{2+}\) in \(\beta\) tubulin. Other chains C & D, and ligands including stathmin like domain were removed from the crystal structure using PyMol [28]. The missing amino acid residues of \(\alpha\) tubulin (amino acid 37 to 47) and \(\beta\) tubulin (amino acid 1, 275–284) were modeled using the MODELLER 9v7 program [29]. The best model was selected on the basis of DOPE (Discrete optimized protein energy) score which is statistical potential optimized for model assessment [29]. The homology models of different tubulin isotypes were then built, using above refined crystal structure of tubulin 1SA0.pdb (Fig 1) as a template, with the help of MODELLER 9v7 [29]. The stereo-chemical quality of template (referred as tubulin 1SA0 hereafter) and different tubulin isotypes were evaluated using PROCHECK [30], Verify-3D [31] and ERRAT [32] to check the reliability of generated models, whose details are provided in Text A in S1 Text.

The energy minimization for 5000 cycles was performed over the tubulin 1SA0 and different tubulin isotypes heterodimers i.e. \(\alpha\beta_{II}\), \(\alpha\beta_{III}\), and \(\alpha\beta_{IV}\), to remove steric clashes using AMBER 12 [33], where initial 200 cycles were done through steepest descent method, followed by remaining cycles through conjugate gradient method. The parameters for GTP, GDP and Mg\(^{2+}\) were obtained from AMBER parameter database [34, 35] for minimization. These energy minimized tubulin 1SA0 and \(\alpha\beta\) tubulin isotype heterodimers were then used for molecular docking of DAMA-colchicine using AutoDock4.2 [36].

**Molecular Docking of DAMA-colchicine and \(\alpha\beta\) Tubulin Isotypes**

To understand the putative binding pocket and the residues involved in the bonding and non-bonding interactions, molecular docking of DAMA-colchicine with tubulin 1SA0 and tubulin isotypes \(\alpha\beta_{II}\), \(\alpha\beta_{III}\) and \(\alpha\beta_{IV}\) were carried out using AutoDock4.2 [36]. The three dimensional co-ordinates of DAMA-colchicine from the crystal structure (PDB ID: 1SA0) were used for molecular docking calculations. Since it is known from earlier studies [37] that colchicine binds at \(\alpha\beta\) tubulin interface [21], hence the putative binding pocket was defined only at the interface of \(\alpha\beta\) tubulin using AutoGrid [36]. The grid was chosen with a grid spacing of 0.375Å centered on the selected flexible residues present in the active site of \(\alpha\beta\) interface. The grid box enclosed the entire colchicine binding site at \(\alpha\beta\) interface, and provided enough conformational space to the DAMA-colchicine for translation and rotation for achieving the best binding conformation.

The Lamarckian genetic algorithm (LGA) was used for docking studies, the step size of 2Å for translation and 50° of rotation were chosen. The maximum number of energy evaluation was set to 25,00,000. Total 50 runs were performed, and for every independent run a maximum number of 27,000 generations were generated on a single population of 150 individuals. The clusters were then compared on the basis of the cluster size and binding energy calculated by AutoDock4.2 scoring function. The lowest energy docked conformation was selected as the probable stable conformation at the \(\alpha\beta\) tubulin interface binding site. The DAMA-colchicine docked complex of tubulin 1SA0 as well as DAMA-colchicine docked complex of tubulin isotypes \(\alpha\beta_{II}\), \(\alpha\beta_{III}\) and \(\alpha\beta_{IV}\) were further used for molecular dynamics simulation study.

**Electrostatic Contact Potential Calculation**

The electrostatic contact potentials were calculated using PyMol [28] using the lowest energy docked complex of DAMA-colchicine with tubulin 1SA0 as well as \(\alpha\beta_{II}\), \(\alpha\beta_{III}\), and \(\alpha\beta_{IV}\) tubulin isotypes after removing \(\alpha\) tubulin. A similar strategy was applied while calculating electrostatic
contact potential using molecular dynamics (MD) simulated structure of tubulin 1SA0 as well as tubulin isotypes $\alpha\beta_{II}$, $\alpha\beta_{III}$, and $\alpha\beta_{IV}$.

**Molecular Dynamics (MD) Simulations**

Molecular dynamics simulations were performed for DAMA-colchicine docked complexes of tubulin 1SA0 and tubulin isotypes ($\alpha\beta_{II}$, $\alpha\beta_{III}$, and $\alpha\beta_{IV}$) using the sander module of AMBER 12 [33]. The AMBER ff99SB force field was used for tubulin, the parameter for GTP, GDP and Mg$^{2+}$ were obtained from AMBER parameter database [34, 35]. DAMA-colchicine was parameterized using the 'Antechamber' module of AMBER 12 similar to earlier studies [18]. The Generalized Born Surface Area (GBSA) implicit solvent model was used to mimic the aqueous environment with parameters described by Tsui [38]. Implicit modeling studies are now widely used to understand the protein-ligand interactions as well as protein folding [18, 39, 40]. The molecular dynamics simulations were performed using the approach used in earlier studies [18]; which are as follows: The energy minimization was performed for 5000 cycles, initial 2000 cycles were done through steepest descent method, followed by 3000 cycles of conjugate gradient method on all atoms of $\alpha\beta$ tubulin isotype complex. Next, the system was heated to 300 K for 50ps, shake algorithm was applied with a restraint weight of 2 kcal/mol Å$^2$. Heating was followed by the equilibration for 500 ps steps. The final production run was performed for 25 ns for each system i.e. tubulin 1SA0 as well as tubulin isotypes ($\alpha\beta_{II}$, $\alpha\beta_{III}$, $\alpha\beta_{IV}$). The non-bonded cutoff distance was set to 15 Å, and trajectories were propagated at 2fs time step, applying shake to freeze the bonds involving hydrogen atoms. The trajectories were saved after each 0.2ps time interval. The PTRAJ module of AMBER 12 was used for analysis of the post molecular dynamics simulation trajectories. Trajectories were then visualized and analyzed using the Visual Molecular Dynamics, VMD [41] and PyMol [28]. The movements of tubulin are not very smooth due to presence of thermal fluctuations in simulations. VMD can smooth the animated trajectories by averaging over a given number of frames. The animations/movies shown in Movies S1–S4 Movies were obtained by setting the Trajectory Smoothing Window Size for tubulin between 5 and 7, and for DAMA-colchicine between 2 and 4.

**Binding Free Energy Calculations**

To further investigate the differential binding affinity of different human tubulin isotypes towards DAMA-colchicine, we calculated the binding free energy using MM-GBSA method, which is implemented in the AMBER 12 software [33]. Binding free energy calculations were performed using the mmpbsa module of AMBER 12 software using pairwise Generalized Born model [31]. The binding free energy were calculated using 10000 frames from last 2ns MD trajectories with an interval of 5 for each system. The free energy of complex, receptor and ligand is calculated and energy is estimated as follows in AMBER 12.

$$\Delta G_{\text{bind, solvated}} = G_{\text{complex, solvated}} - G_{\text{receptor, solvated}} - G_{\text{ligand, solvated}}$$  \hspace{1cm} (1)

The binding free energies, $\Delta G_{\text{solvated}}$, is calculated by using following equation using the MM-GBSA method.

$$\Delta G_{\text{solvated}} = E_{\text{gas}} + E_{\text{sol}} - T \Delta S_{\text{solvent}}$$ \hspace{1cm} (2)

$$E_{\text{gas}} = E_{\text{int}} + E_{\text{ele}} + E_{\text{vdw}}$$ \hspace{1cm} (3)

Where, $E_{\text{int}} = E_{\text{bond}} + E_{\text{angle}} + E_{\text{torium}}$ \hspace{1cm} (4)
Where, $E_{\text{gas}}$ is the gas-phase energies are often molecular mechanical energies from force field. $E_{\text{int}}$ is internal energy which consists of $E_{\text{bond}}$, $E_{\text{angle}}$ and $E_{\text{torsion}}$ which are the bond, angle and torsion energies respectively. The $E_{\text{ele}}$ and $E_{\text{vdw}}$ are the electrostatic and van der Waals interactions energies. The $E_{\text{sol}}$ is the solvation energy and is given by

$$E_{\text{sol}} = E_{\text{polar}} + E_{\text{non-polar}}$$

$$E_{\text{nonpol}} = \gamma \text{SASA}$$

The $E_{\text{sol}}$ is the solvation energy contributions that can be decomposed into the polar and non-polar energy. The polar solvation contribution is calculated by solving the Generalized Born (GB) equation; whereas non polar solvation is estimated by the solvent accessible surface area (SASA), using a water probe radius of 1.4 Å. The surface tension constant ($\gamma$) was set to 0.0072 kcal/molÅ$^2$. The entropy contribution was omitted in this study [42, 43] as entropy calculations are computationally expensive. Thus our binding free energy calculations are similar to earlier studies on tubulin and anticancer drugs [11, 44, 45], and Streptococcus suis R61 and cefuroxime drug [46]. The binding free energy calculated will be lower if the entropy contribution is included. Here, we can avoid the need to explicitly calculate the entropy for comparing the relative trend of binding free energies of different isotypes as they are related systems (there is a difference of few residues among them) with respect to experimentally measured relative trend of binding free energy of different isotypes. Thus, one can assume that the solute entropy will be the roughly same for each of these systems which are being compared, and would change the binding free energy by roughly same amount. In mmpbsa module, bonded energy terms ($E_{\text{int}}$) are not printed for any one-trajectory simulation by default. They are computed and their differences are calculated. However, they are not shown (nor included in the total) in output of mmpbsa module unless specifically asked for because they should cancel completely.

**Results and Discussion**

**Sequence Analysis of αβ Tubulin Isotypes**

The multiple sequence alignment of bovine βII tubulin and human β-tubulin isotypes were performed using online multiple sequence analysis tool of EMBL-EBI [26]. The sequence analysis study shows differences in residue composition at different locations in βII, βIII and βIV isotypes. The analysis of colchicine binding pocket of βIII isotype shows changes of three residues i.e. Cys239 to Ser, Ala315 to Thr, and Thr351 to Val (Fig 2), whereas βII isotype contains change of only a single residue i.e. Val316 to Ile at the colchicine binding site. There is no residue change observed in isotype βIV at the colchicine binding pocket (Fig 2). Such differences in the colchicine binding site residues among the isotype βII and βIII might contribute in the differential binding of DAMA-colchicine, as observed previously for colchicine [24]. Hence, we performed homology modeling of these tubulin isotypes, followed by docking of DAMA-colchicine, molecular dynamics simulations and binding energy calculations, to understand the effect of change of residue composition observed in different isotypes on the binding of DAMA-colchicine.

**Molecular Docking of αβ Tubulin Isotypes with DAMA-colchicine**

First, we performed a control docking of tubulin 1SA0 with DAMA-colchicine using AutoDock4.2. The binding energy of the minimum energy docked conformation was found to be -10.70 kcal/mol (Table 1). DAMA-colchicine prefers α-tubulin and β-tubulin interface in tubulin 1SA0 (Fig 3A) similar to the crystal structure [21]. The root mean square deviation (RMSD)
between the ‘predicted’ and ‘crystallographically’ determined binding modes of DAMA-colchicine was found to be 1.2 Å (Table 1). The RMSD in the range of 2–3 Å indicates appropriate docking [27, 36]. The analysis of binding site residues lying within 4 Å distance indicated that DAMA-colchicine is surrounded by both hydrophobic and hydrophilic residues (Table 2), and stabilized by hydrogen bonding interactions with residues Cys-239 (2.20 Å), Lys-350 (2.31 Å) and Val-181 (1.91 Å) given in Table 1. Cys-239 interacts with the trimethoxy benzene group and Lys-350 and Val-181 interact with the methoxytropone ring of DAMA-colchicine. These hydrogen bonding interactions are shown in.

Fig 2. Multiple sequence analysis of tubulin 1SA0 and human β-tubulin isotypes. The isotype βIII shows change of Ala315 to Thr, Cys239 to Ser, and Thr351-to Val; isotype βII change of Val316 to Ile at the colchicine binding pocket. Region of changed residues at colchicine binding pocket are shown in red color.

doi:10.1371/journal.pone.0156048.g002
The molecular docking of DAMA-colchicine on different human tubulin isotypes were performed using the same protocol as used for the control docking of tubulin 1SA0. For docking analysis, we selected the lowest energy docked conformation of DAMA-colchicine with αβ\(^\text{II}\), αβ\(^\text{III}\) and αβ\(^\text{IV}\) tubulin isotypes. In tubulin isotypes, DAMA-colchicine prefers αβ\(^\text{II}\)-tubulin interface similar to tubulin 1SA0 (Fig 3A) and crystal structure [21]. The RMSD between ‘predicted’ and ‘crystal structure’ determined binding modes of DAMA-colchicine for αβ\(^\text{II}\) isotype (Fig 3B), αβ\(^\text{III}\) isotype (Fig 3C) and for αβ\(^\text{IV}\) isotype (Fig 3D) were 2.4 Å, 5.2 Å and 2.1 Å, respectively (Table 1). In the αβ\(^\text{III}\) isotype, DAMA-colchicine prefers a different orientation at the interface. The higher RMSD value for αβ\(^\text{III}\) isotype suggests that the changed residue composition (Ser-239, Thr-315, and Val-351) at the colchicine binding pocket might affect the binding. The analysis of docking complex of αβ\(^\text{II}\) tubulin isotype and DAMA-colchicine (Fig 3B) shows that the DAMA-colchicine binding pocket of αβ\(^\text{II}\) tubulin isotype is amphipathic in nature within 4 Å distance. The residues present around the 4Å distance of DAMA-colchicine are listed in Table 2. The binding energy of DAMA-colchicine was estimated to be -10.45 kcal/mol (Table 1). The analysis of docked complex of αβ\(^\text{III}\) tubulin isotype and DAMA-colchicine (Fig 3C) shows that DAMA-colchicine forms hydrogen bonding with residue Lys-350 (2.07 Å), Cys-239 (2.05 Å) and Asn-256 (2.15 Å) (Table 1). Here, Lys-350 interacts with the methoxytropane ring, Asn-258 with mercaptoacetyl group and Cys-239 with trimethoxy benzene ring of DAMA-colchicine (Fig B in S5 Fig). The analysis of docking complex of αβ\(^\text{III}\) tubulin isotype and DAMA-colchicine (Fig 3B) shows that DAMA-colchicine forms hydrogen bonding with residue Lys-350 (2.65Å) of β-tubulin and Asn-101 (2.20Å) of α-tubulin. Due to an altered orientation of DAMA-colchicine, Lys-350 interacts with mercaptoacetyl group and Asn-101 with trimethoxy benzene ring of DAMA-colchicine (Fig C in S5 Fig).

### Table 1. RMSD of docked DAMA-colchicine relative to crystal structure, binding energy and hydrogen bonding interactions in tubulin 1SA0, and human αβ\(^\text{II}\), αβ\(^\text{III}\) and αβ\(^\text{IV}\) tubulin isotypes.

| Protein system | RMSD of DAMA-colchicine (Å) | Binding energy\(^a\) (kcal/mol) | Hydrogen bonding interactions | Figure reference |
|----------------|-----------------------------|-----------------------------------|------------------------------|-----------------|
| Tubulin 1SA0   | 1.2                         | -10.70                            | Cys-239-HG...O3-COL 2.20    | 3A, Fig A in S5 Fig |
|                |                              |                                   | Lys-350-HG...O5-COL 2.31    |                 |
|                |                              |                                   | Val-181-HN...O5-COL 1.91   |                 |
| αβ\(^\text{II}\) isotype | 2.4                         | -10.45                            | Lys-350-HZ3...O5-COL 2.07 | 3B, Fig B in S5 Fig |
|                |                              |                                   | Cys-239-HG...O3-COL 2.05    |                 |
| αβ\(^\text{III}\) isotype | 5.2                         | -6.58                             | Lys-350-HZ3...S1-COL 2.65  | 3C, Fig C in S5 Fig |
|                |                              |                                   | Asn-101-2HD...O3-COL 2.20  | 151.58          |
| αβ\(^\text{IV}\) isotype | 2.1                         | -10.74                            | Lys-350-HZ1...O5-COL 2.25  | 3D, Fig D in S5 Fig |
|                |                              |                                   | Cys-239-HG...O3-COL 2.08    | 160.26          |

\(^a\)Binding energy values are obtained from the lowest energy DAMA-colchicine docked complex.

doi:10.1371/journal.pone.0156048.t001

The molecular docking of DAMA-colchicine on different human tubulin isotypes were performed using the same protocol as used for the control docking of tubulin 1SA0. For docking analysis, we selected the lowest energy docked conformation of DAMA-colchicine with αβ\(^\text{II}\), αβ\(^\text{III}\) and αβ\(^\text{IV}\) tubulin isotypes. In tubulin isotypes, DAMA-colchicine prefers αβ-tubulin interface similar to tubulin 1SA0 (Fig 3A) and crystal structure [21]. The RMSD between 'predicted' and 'crystal structure' determined binding modes of DAMA-colchicine for αβ\(^\text{II}\) isotype (Fig 3B), αβ\(^\text{III}\) isotype (Fig 3C) and for αβ\(^\text{IV}\) isotype (Fig 3D) were 2.4 Å, 5.2 Å and 2.1 Å, respectively (Table 1). In the αβ\(^\text{III}\) isotype, DAMA-colchicine prefers a different orientation at the interface. The higher RMSD value for αβ\(^\text{III}\) isotype suggests that the changed residue composition (Ser-239, Thr-315, and Val-351) at the colchicine binding pocket might affect the binding.

The analysis of docking complex of αβ\(^\text{II}\) tubulin isotype and DAMA-colchicine (Fig 3B) shows that the DAMA-colchicine binding pocket of αβ\(^\text{II}\) tubulin isotype is amphipathic in nature within 4 Å distance. The residues present around the 4Å distance of DAMA-colchicine are listed in Table 2. The binding energy of DAMA-colchicine was estimated to be -10.45 kcal/mol (Table 1). The analysis of docked complex of αβ\(^\text{II}\) tubulin-DAMA-colchicine shows that DAMA-colchicine forms hydrogen bonding with residue Lys-350 (2.07 Å), Cys-239 (2.05 Å) and Asn-256 (2.15 Å) (Table 1). Here, Lys-350 interacts with the methoxytropane ring, Asn-258 with mercaptoacetyl group and Cys-239 with trimethoxy benzene ring of DAMA-colchicine (Fig B in S5 Fig). In αβ\(^\text{II}\) tubulin-DAMA-colchicine complex, DAMA-colchicine shows similar hydrogen bonding as found in tubulin 1SA0, along with this it also shows additional bonding with Asn-256 (Table 1). The hydrogen bonding interactions for docking complex of αβ\(^\text{II}\) tubulin isotype and DAMA-colchicine are shown in Fig B in S5 Fig.

The analysis of docking complex of αβ\(^\text{III}\) tubulin isotype and DAMA-colchicine (Fig 3C) shows that the DAMA-colchicine prefers a different orientation at the αβ\(^\text{III}\) tubulin interface (Fig 3C) as compared to tubulin 1SA0 (Fig 3A) and αβ\(^\text{II}\) (Fig 3B). The residues present around the 4Å distance of DAMA-colchicine are listed in Table 2. The binding energy of DAMA-colchicine for αβ\(^\text{III}\) was estimated to be -6.58 kcal/mol by docking analysis (Table 1). DAMA-colchicine forms hydrogen bonding (Table 1) with residues Lys-350 (2.65Å) of β-tubulin and Asn-101 (2.20Å) of α-tubulin. Due to an altered orientation of DAMA-colchicine, Lys-350 interacts with mercaptoacetyl group and Asn-101 with trimethoxy benzene ring of DAMA-colchicine (Fig C in S5 Fig).
An analysis of docking complex of αβIV tubulin isotype and DAMA-colchicine (Fig 3D) shows that, DAMA-colchicine also prefers αβIV tubulin interface similar to tubulin 1SA0 and tubulin isotypes. (A) Tubulin 1SA0-DAMA-colchicine complex. (B) αβII tubulin isotype-DAMA-colchicine complex (C) αβIII tubulin isotype-DAMA-colchicine complex (D) αβIV tubulin isotype-DAMA-colchicine complex.

![Fig 3. Comparison of crystal structure and docked conformation of DAMA-colchicine in tubulin 1SA0 and human αβ-tubulin isotypes. Color scheme for α-tubulin is green, cyan and β-tubulin is tv_blue for tubulin 1SA0 tv_red for isotype βII, tv_yellow for isotype βIII and violet for isotype βIV. Crystal structure of DAMA-colchicine is shown in magenta color, while DAMA-colchicine after docking is shown in green color. The oxygen, nitrogen and sulphur atoms of DAMA-colchicine are shown in red, blue and pale yellow color, respectively. The DAMA-colchicine prefers the αβ tubulin interface in tubulin 1SA0 and tubulin isotypes. (A) Tubulin 1SA0-DAMA-colchicine complex. (B) αβII tubulin isotype-DAMA-colchicine complex (C) αβIII tubulin isotype-DAMA-colchicine complex (D) αβIV tubulin isotype-DAMA-colchicine complex.

Table 2. Residues present around the 4 Å distances of DAMA-colchicine in tubulin 1SA0, and human αβ tubulin isotypes after docking.

| Protein | Residues around 4 Å distance of DAMA-colchicine |
|---------|--------------------------------------------------|
| **Tubulin 1SA0** | **β-tubulin residues:** Cys-239, Leu-246, Ala-248, Lys-252, Leu-253, Asn-256, Met-257, Thr-312, Val-313, Val-316, Asn-348, Lys-350, Ala-352. **α-tubulin residues:** Asn-101, Ser-178, Thr-179, Ala-180, Val-181. |
| **αβII isotype** | **β-tubulin residues:** Val-236, Cys-239, Leu-246, Ala-248, Lys-252, Leu-253, Asn-256, Met-257, Val-313, Val-314, Val-316, Lys-350, Ala-352. **α-tubulin residues:** Asn-101, Ser-178, Thr-179, Ala-180, Val-181. |
| **αβIII isotype** | **β-tubulin residues:** Leu-246, Ala-248, Lys-252, Asn-256, Ala-314, Ala-315, Val-316, Lys-350, Thr-351, Ala-352. **α-tubulin residues:** Asn-101, Pro-175, Ser-178, Thr-179, Ala-180. |
| **αβIV isotype** | **β-tubulin residues:** Cys-239, Leu-246, Ala-248, Lys-252, Leu-253, Asn-256, Val-313, Ala-314, Ala-315, Val-316, Asn-348, Lys-350, Thr-351, Ala-352. **α-tubulin residues:** Asn-101, Thr-179, Ala-180, Val-181. |
colchicine are shown in Table 2, DAMA-colchicine is surrounded by more residues from the β-tubulin chain and very few residues of α-tubulin. The lowest binding energy of DAMA-colchicine was estimated to be -10.74 kcal/mol by docking analysis Table 1. DAMA-colchicine forms hydrogen bonding interactions with Lys-350 (2.25Å) and Cys-239 (2.08Å). Lys-350 interacts with the oxygen atom of methoxyphtropone ring and Cys-239 with trimethoxy benzene ring at the binding site. These interactions are shown in Fig D in S5 Fig.

It has been observed that, in αβII and αβIV tubulin isotype Lys-350 forms hydrogen bonding interactions with methoxyphtropone ring and Cys-239 with trimethoxy benzene ring of DAMA-colchicine. Whereas, in the altered orientation of DAMA-colchicine at the interface of αβIII isotype, Lys-350 forms hydrogen bonding with mercaptoacetyl group of B ring. The changes in residue composition at the binding pocket produces a profound effect on the binding of DAMA-colchicine. Hence the residues such as Cys-239 and Lys-350 could play a crucial role in binding of DAMA-colchicine.

Molecular Docking studies show that binding energies of tubulin isotypes for DAMA-colchicine (Table 1) are in the order αβIV ≈ αβII >> αβIII, whereas experimentally measured binding energies of tubulin isotypes for colchicine are in the order αβIV > αβII ≈ αβIII for these three isotypes in bovine (Text B in S1 Text)[2].

We calculated electrostatic contact potential over the β-tubulin-DAMA-colchicine complex using PyMol [28], since changes in residue composition observed in β-tubulin isotypes show a pronounced effect on the binding of DAMA-colchicine (S6 Fig). The electrostatic contact potential of tubulin 1SA0 (Fig A in S6 Fig), αβII and αβIV tubulin isotypes (Fig B in S6 Fig and Fig D in S6 Fig) shows that the DAMA-colchicine is located inside the binding pocket of β-tubulin. While in case of αβIII tubulin isotype, DAMA-colchicine is partially buried inside the binding pocket (Fig C in S6 Fig). Electrostatic potential calculations further confirm that the DAMA-colchicine takes different orientations at the αβ interface of αβIII tubulin isotype. Therefore, to understand the detailed molecular mechanism of differential binding of tubulin isotypes for DAMA-colchicine, we performed molecular dynamics simulations and binding free energy calculations.

**Molecular Dynamics (MD) Simulation of Tubulin heterodimers-DAMA-colchicine Complexes**

Molecular dynamics simulations were performed using the lowest energy DAMA-colchicine docked complex of tubulin heterodimers as starting structures (Fig 3A–3D). The primary analysis was made by looking at the MD simulation stability and analysis of protein structure. To check the stability of molecular dynamics simulation, the RMSD of the Cα backbone atom of a production dynamics for tubulin 1SA0 and tubulin isotype heterodimers were calculated and are shown in Fig 4. Structurally, the human β-tubulin isotypes differ in composition due to last 15 to 20 C-terminal amino acids (Fig 2), which are the putative binding sites for many microtubule associated proteins (MAPs). Our template structure tubulin 1SA0 doesn’t have C-terminal region in its crystal structure [21]. Therefore, the RMSD of αβ tubulin isotypes considering the last 15 to 20 C-terminal amino acid region of β-tubulin shows an increased RMSD. Hence, we calculated the RMSD excluding the C-terminal region starting from amino acid Ala-428. The RMSD analysis shown in Fig 4 suggests that tubulin 1SA0, αβIII and αβIV deviate to quite some extent from their starting conformations and reached their equilibrium conformations after 15ns, and then retained their stability with fluctuations between 2.2–2.7Å. To understand the compactness of tubulin structure, we calculated the radius of gyration (Rg) and root mean square of fluctuations (RMSF) of tubulin 1SA0 and different tubulin isotypes.

It is seen that the T7 loop starts moving backwards and DAMA-colchicine is adapted inside the β-tubulin binding site (S1, S2 and S4 Movies) tubulin 1SA0 and tubulin isotypes αβII and
Whereas, in the βIII tubulin isotype DAMA-colchicine is expelled from the binding pocket. It starts moving out to the surface of the interface (S3 Movie) and closure of the binding pocket starts thereafter. In case of αβIII tubulin isotype, T7 loop starts to move forward while the H7-H8 helix shows less fluctuation as compared to tubulin 1SA0 and other isotypes. The radius of gyration (Rg) value indicates the level of compactness of a protein and it has been applied to obtain an insight into the stability of a system during MD simulation [47]. Since change in residue composition are present only on β monomers, the radius of gyration of only β monomer of tubulin 1SA0 and tubulin isotypes were calculated and are shown in S7 Fig. The radius of gyration results in S7 Fig shows the compactness and stable behavior of β-tubulin structures, during molecular dynamics simulations, for tubulin 1SA0 and three β-tubulin isotypes. To understand the effect of changes in residue composition in β-tubulin isotypes, the root mean square fluctuations were calculated and are discussed in detail below.

**Analysis of Root Mean Square Fluctuations (RMSF)**

RMSF plots provide information on the flexible regions of the MD simulated structures. RMSF mainly calculates the degree of movement of Cα atoms around their average positions. The highly flexible regions show higher RMSF value while the constrained regions show low RMSF value. We have calculated the RMSF of human tubulin isotypes βII, βIII and βIV using the PTRAJ module of AMBER 12. All the β-tubulin isotypes show flexibility below the range of 5Å (Fig 5). A comparison of RMSF plots of different isotypes shows that H6-H7 (210–220) helix
and M loop (272–287) of βIII isotype shows higher fluctuations than βI and βIV isotypes. Hence, for detailed understanding of the bonding and nonbonding interactions of residues at the binding site of DAMA-colchicine, we analyzed the MD simulated structures of tubulin 1SA0 and tubulin isotypes.

**Analysis of MD simulation structures of αβ tubulin-DAMA-colchicine complex**

The hydrogen bonding interactions and residues lying around 4 Å distance of ligand after MD simulations were used to understand the binding mode of DAMA-colchicine. The molecular dynamics simulated structures for each system i.e. tubulin 1SA0, αβII isotype, αβIII isotype and αβIV isotype (Fig 6A–6D) were considered for the analysis of bonding and non-bonding residues present around DAMA-colchicine. DAMA-colchicine prefers αβ interface for tubulin 1SA0 (Fig 6A), αβII (Fig 6B) and αβIV (Fig 6D) tubulin isotypes, except for the αβIII (Fig 6C) tubulin isotype. In αβIII tubulin, DAMA-colchicine moves from the initial docked position (Fig 3C) and goes to the surface of interface (Fig 6C and S3 Movie). Here, we considered only the RMSD of DAMA-colchicine. The RMSD between molecular dynamics simulated ‘Starting structure’ i.e. docked structure and ‘End structure’ determined binding modes of DAMA-colchicine was 3.59 Å for tubulin 1SA0, 4.32 Å for αβII isotype, 11.45 Å for αβIII isotype and 2.94 Å for αβIV isotype (Table 3). Thus, root mean square deviations (RMSD) analysis shows that DAMA-colchicine largely deviates from the starting position in αβIII tubulin isotype (Fig 6C). The hydrogen bonding and residues lying around the 4Å distance of DAMA-colchicine in tubulin 1SA0 and tubulin isotypes are shown in Table 3 and Table 4 respectively.
The analysis of MD simulated representative structure of tubulin 1SA0-DAMA-colchicine complex shows the hydrogen bonding interactions of DAMA-colchicine with Glu-198 (2.35 Å), Cys-239 (3.12 Å), Leu-246 (2.37 Å), Leu-253 (3.43 Å), Asn-256 (2.78 Å) and Lys-350 (3.20 Å) as shown in Table 3. Asn-256 and Lys-350 interact with the mercaptoacetyl group; Glu-198, Leu-253 and Cys-239 interact with the trimethoxy benzene ring and Leu-246 with methoxytropone ring of DAMA-colchicine. In tubulin 1SA0, DAMA-colchicine interacts mostly with the β-tubulin residues at the binding pocket (Table 4). The interactions are shown in Fig A in S8 Fig. In the MD simulated αβII tubulin-DAMA-colchicine complex, DAMA-colchicine shows hydrogen bond with residues Cys-239 (2.61 Å), Leu-246 (2.31 Å), Asn-256 (3.35 Å) and Ala-244 (2.80 Å) of β-tubulin (Table 3 and Fig B in S8 Fig). The Asn-256 interacts with the methoxytropone ring, Leu-246 interact with mercaptoacetyl group and Cys-239 with trimethoxy ring of DAMA-colchicine.

Analysis of αβIII tubulin-DAMA-colchicine complex shows hydrogen bonding of DAMA-colchicine with residues Leu-246 (2.71 Å) of β tubulin and Asn-348 (3.10 Å) and Pro-222 (2.40 Å) of α tubulin in binding pocket (Table 4 and Fig C in S8 Fig). Comparing the residues lying around the 4 Å distance of DAMA-colchicine in the initial structure (Table 2) and the MD simulated end structure (Table 4), it is clearly seen that DAMA-colchicine shifts from the
initial binding position and moves out to the surface of interface. In this case, the T5 loop of α-tubulin and B9 sheet β-tubulin shows large conformational changes, whereas the T7 loop comes forward resulting into the closing of the binding pocket (S3 Movie).

Finally, analysis of αβ IV tubulin-DAMA-colchicine complex shows hydrogen bonding between DAMA-colchicine and Leu-246 (3.26Å), Leu-253 (2.86Å), Asn-256 (3.40Å) and Lys-350 (3.30Å) of β chain and Ala-180 (2.81Å) of α chain (Table 3 and Fig D in S8 Fig). The residues Asn-256 and Lys-350 interact with methoxytropone ring, Leu-248 with mercaptoacetyl group and Leu-253 with the trimethoxy benzene ring. In the tubulin 1SA0 and αβ IV tubulin, common amino acids interacting with DAMA-colchicine are Leu-246, Leu-253, Asn-256 and Lys-350 (Table 3).

| Protein structure | RMSD of DAMA-colchicine after simulation Å | Hydrogen bonding interactions | Figure Reference |
|-------------------|------------------------------------------|-------------------------------|------------------|
| Tubulin 1SA0      | 3.59                                     | Glu-198 OE2...HC6-COL 2.35 111.32 | 6A, Fig A in S8 Fig |
|                   |                                          | Cys-239 HG...O1-COL 3.12 126.31 |
|                   |                                          | Leu-246 HD11...O5-COL 2.37 156.96 |
|                   |                                          | Leu-253 HD13...O2-COL 3.43 111.44 |
|                   |                                          | Asn-256 HD21...O4-COL 2.78 118.59 |
|                   |                                          | Lys-350-HB3...O6-COL 3.20 141.94 |
| αβII isotype      | 4.32                                     | Cys-239-HC...O3-COL 2.61 140.35 | 6B, Fig B in S8 Fig |
|                   |                                          | Leu-246 HD12...N1-COL 3.19 156.52 |
|                   |                                          | Leu-246-O...HC6-COL 2.31 155.94 |
|                   |                                          | Asn-256 HB3...O5-COL 3.35 132.55 |
|                   |                                          | COL-O3...Ala-244 2.80 128.89 |
| αβIII isotype     | 11.45                                    | Pro-222 HC...O1-COL 2.40 125.75 | 6C, Fig C in S8 Fig |
|                   |                                          | Leu-246 HB2...O2-COL 2.71 149.62 |
|                   |                                          | Asn-348 HD22...O4-COL 3.10 107.48 |
| αβIV isotype      | 2.94                                     | Leu-246 HD11...N1-COL 3.26 139.77 | 6D, Fig D in S8 Fig |
|                   |                                          | Leu-253 HD13...O3-COL 2.86 108.23 |
|                   |                                          | Asn-256 HB3...O-COL 3.40 121.40 |
|                   |                                          | Lys-350 HG2...O5-COL 3.30 129.75 |
|                   |                                          | Ala-180-CH...O4-COL 2.81 143.38 |

doi:10.1371/journal.pone.0156048.t003

Table 4. Residues present around the 4 Å distances of DAMA-colchicine in tubulin 1SA0 and tubulin isotypes after simulation.

| Protein     | Residues around 4 Å distance of DAMA-colchicine after simulation |
|-------------|------------------------------------------------------------------|
| Tubulin 1SA0| **β-tubulin residues:** Glu-200, Tyr-202, Gly-235, Val-238, Thr-240, Cys-239, Lys-246, Ala-248, Leu-250, Lys-252, Leu-253, Asn-256, Ala-314, Ala-315, Val-316, Lys-350, Thr-351, Ala-352, Ile-376. **α-tubulin residues:** Asn-101, Ser-178, Thr-179. |
| αβII isotype| **β-tubulin residues:** Cys-239, Pro-243, Gly-244, Gln-245, Leu-246, Lys-252, Leu-253, Asn-256, Met-257, Ala-314, Ile-316, Asn-347, Lys-350, Thr-351, Ala-352, Cys-354. **α-tubulin residues:** Thr-179, Ala-180, Val-181. |
| αβIII isotype| **β-tubulin residues:** Gln-245, Leu-246, Asp-328, Leu-331, Asn-347, Val-349, Lys-350, Val-351, Ala-352. **α-tubulin residues:** Gln-176, Val-177, Ser-178, Thr-179, Ala-180, Val-181, Thr-210, Glu-220, Arg-221. |
| αβIV isotype| **β-tubulin residues:** Glu-199, Tyr-200, Val-236, Cys-239, Leu-240, Leu-250, Lys-252, Leu-253, Ala-254, Asn-256, Met-257, Phe-266, Thr-312, Ala-314, Asn-348, Lys-350, Ile-376. **α-tubulin residues:** Asn-101, Ser-178, Thr-179, Ala-180, Val-181. |
Our structural analysis of MD simulated tubulin DAMA-colchicine complexes confirms that DAMA-colchicine mostly interacts with the \( \beta \)-tubulin residues. Overall the residues at the binding pocket such as Cys-239, Leu-246, Asn-256, and Leu-253 and Lys-350 of \( \beta \)-tubulin could play an important role in the stabilization of DAMA-colchicine binding. While in \( \alpha \beta \)III, DAMA-colchicine doesn’t show any such interactions with these residues (Table 3). Hence, we considered only \( \beta \)-tubulin and DAMA-colchicine for electrostatic contact potential calculation to understand the binding mode of DAMA-colchicine after molecular dynamics simulation.

The electrostatic potential surfaces show that DAMA-colchicine is located inside the binding cavity of \( \beta \)-tubulin in case of tubulin 1SA0 (Fig A in S9 Fig), \( \alpha \beta \)II tubulin isotype (Fig B in S9 Fig) and \( \alpha \beta \)IV tubulin isotype (Fig D in S9 Fig), whereas in \( \alpha \beta \)III tubulin DAMA-colchicine moves from the initial binding pocket (Fig C in S9 Fig).

The electrostatic and van der Waals interactions along with the hydrogen bonding interactions could also play an important role in the stabilization of the protein-ligand complex. Hence, we further employed MM-GBSA binding free energy calculations, to understand binding free energy differences for tubulin 1SA0 and different tubulin isotypes for DAMA-colchicine.

### Binding Free Energy Calculation

The binding free energy for the tubulin 1SA0 and different tubulin isotypes are shown in Table 5. As stated earlier, the entropic contribution to the binding free energy was ignored in these calculations.

The estimated binding free energies (\( \Delta E_{\text{bind}} \)) of complexes of DAMA-colchicine with \( \alpha \beta \)III, \( \alpha \beta \)II and \( \alpha \beta \)IV tubulin isotype heterodimers are, -56.74, -51.95 and -64.45 kcal/mol, respectively (Table 5). The \( \alpha \beta \)IV tubulin isotype has the highest binding free energy for DAMA-colchicine, whereas \( \alpha \beta \)III tubulin isotype has the lowest binding free energy among three isotypes (Table 5). The binding free energy (\( \Delta E_{\text{bind}} \)) of tubulin isotype for DAMA-colchicine decreases in the order \( \alpha \beta \)IV > \( \alpha \beta \)II > \( \alpha \beta \)III. The order of decrease is similar to experimentally measured binding energies for colchicine as well as Desacetamidocolchicine for these three isotype from bovine (Text B and Text C in S1 Text) [2, 25]. Relative differences in binding energies are similar to ones measured for Desacetamidocolchicine yet they are very different from ones measured for colchicine (\( \alpha \beta \)IV > \( \alpha \beta \)II \( \simeq \) \( \alpha \beta \)III). Thus, changes in residue composition at the DAMA-colchicine binding site of \( \alpha \beta \)II and \( \alpha \beta \)III tubulin isotype have an impact on the binding free energy (\( \Delta E_{\text{bind}} \)).

The electrostatic (\( \Delta E_{\text{ele}} \)) and van der Waals (\( \Delta E_{\text{vdw}} \)) interactions play a prominent role in binding free energy of protein-ligand complex. The electrostatic energy (\( \Delta E_{\text{ele}} \)) is favorable for binding; the \( \alpha \beta \)III tubulin isotype shows lowest electrostatic interaction energy (\( \Delta E_{\text{ele}} \)) in comparison to \( \alpha \beta \)II and \( \alpha \beta \)IV isotypes. Here, the electrostatic free energy makes the greatest contribution to the binding free-energy (Table 5). The solvation energy (\( E_{\text{solv}} \)) consists of polar and non-polar contributions and is unfavorable for binding. The net binding free energy, which is decided by the competition of \( E_{\text{gas}} \) and \( E_{\text{solv}} \) is lowest for \( \alpha \beta \)III tubulin isotype. Thus, the binding

| Protein          | \( \Delta E_{\text{vdw}} \) | \( \Delta E_{\text{ele}} \) | \( \Delta E_{\text{gas}} \) | \( \Delta E_{\text{solv}} \) | \( \Delta E_{\text{bind}} \) |
|------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Tubulin 1SA0     | -62.99                      | -1327.85                    | -1390.84                    | 1334.73                     | -56.11                      |
| \( \alpha \beta \)II isotype | -54.06                      | -2045.11                    | -2099.17                    | 2042.43                     | -56.74                      |
| \( \alpha \beta \)III isotype | -54.27                      | -1414.59                    | -1468.86                    | 1416.91                     | -51.95                      |
| \( \alpha \beta \)IV isotype  | -64.28                      | -1549.38                    | -1613.66                    | 1549.21                     | -64.45                      |

\( \Delta E_{\text{bind}} = \Delta E_{\text{gas}} + \Delta E_{\text{solv}} = (\Delta E_{\text{vdw}} + \Delta E_{\text{ele}}) + (\Delta E_\text{polar} + \Delta E_{\text{nonpolar}}) \)

doi:10.1371/journal.pone.0156048.t005
free energy calculation supports the results obtained from molecular docking and MD simulation studies that the tubulin isotype αβIII shows less binding affinity for DAMA-colchicine. Binding free energies reported here should not be compared directly with the ones obtained experimentally, as our free energy calculations do not include entropic contributions.

Understanding the Effect of residue variations present in αβIII Tubulin Isotype

It is clear from the docking, molecular dynamics simulation and binding energy calculations that DAMA-colchicine is repelled from the interface of αβIII tubulin isotype (Figs 3 and 6 and Table 5). The colchicine binding pocket of αβIII tubulin isotype has three residue changes Ser-239, Thr315, and Val351. However, it is not clear as to which residues among Ser-239, Thr-315 and Val-351 at the colchicine binding pocket play a major role in affecting the binding of colchicine to αβIII tubulin isotype. In the tubulin 1SA0, amino acid Cys-239 of β-tubulin is involved in β-tubulin recognition site for colchicine [48]. Sulphydryl group of Cys-239 present in βi, βII and βIV isotypes of bovine tubulin is readily oxidized and its oxidation inhibits microtubule assembly [49]. Hence, change of Cys-239 to Ser in αβIII isotype could play a role in affecting the binding of colchicine. In αβIII isotype, there are two other residue changes, Thr315 and Val351 in B8 and B9 beta sheet respectively, which may cause disruption in interactions with helices 9 and 10. Thus, these residue changes in the beta sheet near the colchicine binding region may also affect the colchicine binding. To get a better understanding as to which residues play a major role in the binding of DAMA-colchicine, each of these three residues Ser-239, Thr-315 and Val-351 were in-silico mutated back to the residues found in the tubulin 1SA0 i.e. Cys-239, Ala-315 and Thr-351.

Here, we built four different systems with in-silico mutations: (1) αβIII isotype with Ser239 to Cys (2) αβIII isotype with Thr315 to Ala (3) αβIII isotype Val351 to Thr and (4) αβIII isotype with Ser239-Cys, Thr315-Ala and Val351-Thr similar to tubulin 1SA0 (details of molecular modeling in Text D in S1 Text). The RMSD between the ‘predicted’ and ‘crystallographically’ determined binding modes of DAMA-colchicine, using molecular docking studies, for these four in-silico mutant structures are listed in Table 6. The RMSD of the DAMA-colchicine in these in-silico mutant structures of αβIII isotypes such as Ser239-Cys (Fig A in S10 Fig), Thr315-Ala (Fig B in S10 Fig), Val351-Thr (Fig C in S10 Fig) and Ser239-Cys, Thr315-Ala Val351-Thr (Fig D in S10 Fig) were 9.50 Å, 7.56 Å, 7.69 Å and 2.08 Å, respectively. The RMSD in the range of 2–3 Å indicates appropriate binding [27, 36]. Hence, the RMSD value shows that all residues at the colchicine binding pocket (Ser-239, Thr315, and Val351) play a role in affecting the binding of DAMA-colchicine to αβIII isotype. Further, we also compared the binding energy difference of the minimum energy docked conformations of DAMA-colchicine (Table 6) to these in-silico mutated structures. The binding energy of minimum energy docked DAMA-colchicine with Ser239-Cys (Fig A in S10 Fig), Thr315-Ala (Fig B in S10 Fig), Val351-Thr (Fig C in S10 Fig) and Ser239-Cys, Thr315-Ala Val351-Thr (Fig D in S10 Fig) in-silico mutant structures are -7.95, -6.92, -6.81 and -9.00 kcal/mol, respectively (Table 6).

Table 6. RMSD of DAMA-colchicine relative to crystal structure, binding energy and hydrogen bonding interactions of DAMA-colchicine with in-silico mutant structures of αβIII tubulin isotypes after docking.

| In-silico Mutant structure | RMSD of DAMA-colchicine | Binding energy (kcal mol⁻¹) | Figure reference |
|---------------------------|-------------------------|----------------------------|------------------|
| Ser-239-Cys               | 9.50                    | -7.95                      | Fig A in S10 Fig |
| Thr315-Ala                | 7.56                    | -6.92                      | Fig B in S10 Fig |
| Val351-Thr                | 7.69                    | -6.81                      | Fig C in S10 Fig |
| Ser239-Cys, Thr315-Ala, Val351-Thr | 2.08 | -9.00 | Fig D in S10 Fig |

*Binding energy values are obtained from the lowest energy DAMA-colchicine docked complex.
Hence, the RMSD and binding energy results show that all the mutations Ser-239, Thr-315 and Val-351 collectively affect the binding of DAMA-colchicine to αβIII isotype.

Conclusions

In this study, we investigated the differential binding affinity of human tubulin isotypes αβII, αβIII and αβIV towards DAMA-colchicine using molecular docking, molecular dynamics simulation and binding free energy calculations. The sequence analysis of β-tubulin isotypes showed presence of residue changes at the binding site of isotype βII and βIII that may affect the binding of DAMA-colchicine. The docking results show that DAMA-colchicine prefers the αβ interface of tubulin in tubulin 1SA0, αβII and αβIV isotype as similar to the crystal structure, whereas it prefers a different orientation in αβIII isotype. After docking, the RMSD values for ‘predicted’ and ‘crystal structure’ of DAMA-colchicine in αβII, αβIII and αβIV tubulin isotypes are 2.4Å, 5.2Å and 2.1Å respectively, indicating that residue changes at the binding site of αβIII affect the binding of DAMA-colchicine. We further find that Lys-350 forms hydrogen bond with methoxytropone ring of DAMA-colchicine in αβII and αβIV, whereas Lys-350 forms hydrogen bond with mercaptoacetyl group of DAMA-colchicine in αβIII. The hydrogen bonding of Lys-350 with mercaptoacetyl group alters the binding pose of the DAMA-colchicine in the binding pocket in αβIII. This could explain the order of binding affinities (αβIV > αβII > αβIII) observed for DAMA-colchicine which is different from experimentally measured binding energies of tubulin isotypes for colchicine (αβIV > αβII ~ αβIII).

Molecular dynamics (MD) simulations were performed on tubulin-DAMA-colchicine docked conformation to further investigate the differential binding affinity of DAMA-colchicine for tubulin isotypes. Our MD simulations show that DAMA-colchicine is adapted inside the β-tubulin binding site in tubulin isotypes αβII and αβIV, whereas DAMA-colchicine is expelled from the binding pocket in the αβIII tubulin isotype. The RMSD of the initial and final binding poses of DAMA-colchicine after MD simulation in αβII, αβIII and αβIV tubulin isotypes are 4.32Å, 11.45Å and 2.94Å respectively.

Further, the electrostatic and van der Waals interactions play important roles in the binding of DAMA-colchicine at αβ tubulin interface in tubulin 1SA0 and αβIV, whereas the loss of these interactions in αβII and αβIII may affect the binding. In addition, the docking study of αβIII with in-silico mutations confirms that, all three changed residues at the binding site of αβIII isotype are collectively responsible for affecting the binding of DAMA-colchicine.

Our computational studies not only provide a detailed understanding of differential binding affinity of DAMA-colchicine for tubulin isotypes but they also provides another example of how sensitive the binding of colchicine congeners is to alternations of the side chain of the B-ring. This detailed understanding of the tubulin isotype and DAMA-colchicine interactions will provide some useful insights for designing better analogues in future.

Supporting Information

S1 Fig. (A) PROCHECK plot (B) Verify-3D plot and (C) ERRAT plot for tubulin 1SA0. The PROCHECK result shows that 76.5% residues are in favored regions, 18% residues in additional allowed regions, 4.1% of residues in generously allowed regions and 1.3% residues in disallowed regions. The red region in Ramachandran plot is ‘most favoured’, bright yellow is ‘additional allowed’, dull yellow is the ‘generously allowed’ and white is the ‘disallowed’ region. The VERIFY-3D score was 97.86, and the ERRAT score was 77.25, further indicating the good quality of the template model (Tubulin 1SA0.pdb).

(PDF)
S2 Fig. (A) PROCHECK plot (B) Verify-3D plot and (C) ERRAT plot for αβII tubulin isotype. The PROCHECK result shows that 87.1% residues are in favored regions, 10.5% residues in additional allowed regions, 1.3% of residues in generously allowed regions and 1.0% residues in disallowed regions. The red region in Ramachandran plot is ‘most favoured’, bright yellow is ‘additional allowed’, dull yellow is the ‘generously allowed’ and white is the ‘disallowed’ region. The VERIFY-3D score was 95.81% and the ERRAT score was 88.05, further indicating the good quality of the model of human αβII tubulin isotype.

S3 Fig. (A) PROCHECK plot (B) Verify-3D plot and (C) ERRAT plot for αβIII tubulin isotype. The PROCHECK result shows that 87.5% residues are in favored regions, 10.1% residues in additional allowed regions, 1.4% of residues in generously allowed regions and 1.0% residues in disallowed regions. The red region in Ramachandran plot is ‘most favoured’, bright yellow is ‘additional allowed’, dull yellow is the ‘generously allowed’ and white is the ‘disallowed’ region. The VERIFY-3D score was 95.25% and the ERRAT score was 88.60, further indicating the good quality of the model of human αβIII tubulin isotype.

S4 Fig. (A) PROCHECK plot (B) Verify-3D plot and (C) ERRAT plot for αβIV tubulin isotype. The PROCHECK result shows that 86.6% residues are in favored regions, 11.4% residues in additional allowed regions, 1.2% of residues in generously allowed regions and 0.8% residues in disallowed regions. The red region in Ramachandran plot is ‘most favoured’, bright yellow is ‘additional allowed’, dull yellow is the ‘generously allowed’ and white is the ‘disallowed’ region. The VERIFY-3D score was 94.99% and the ERRAT score was 89.85, further indicating the good quality of the model of human αβIV tubulin isotype.

S5 Fig. Hydrogen bonding interactions of DAMA-colchicine with tubulin 1SA0 and tubulin isotypes after docking. Color scheme for α-tubulin is green_cyan and β-tubulin is tv_blue for tubulin 1SA0, tv_red for isotype βII, tv_yellow for isotype βIII and violet for isotype βIV. Crystal structure of DAMA-colchicine after docking is shown in green color. The oxygen, nitrogen and sulphur atoms of DAMA-colchicine has are shown in red, blue and pale yellow color, respectively. The hydrogen bonds are shown as black dotted line between tubulin residues and DAMA-colchicine, (A) Hydrogen bonding between DAMA-colchicine (green color) and tubulin 1SA0 residues i.e. Cys-239(2.20Å), Lys-350(2.31Å) and Val-181(1.91Å) at the interface binding pocket. (B) Hydrogen bonding between DAMA-colchicine and αβII tubulin isotype residues i.e. Lys-350(2.07Å), Cys-239(2.05Å) and Asn-256(2.15Å) at binding pocket. (C) Hydrogen bonding interaction between with DAMA-colchicine and αβIII tubulin isotype residues i.e. Lys-350(2.65Å) of β-tubulin and Asn-101(2.20Å) α-tubulin. (D) Hydrogen bonding between DAMA-colchicine and αβIV tubulin isotype i.e. Cys-239(2.08Å) and Lys-352(2.25Å) in the binding pocket.

S6 Fig. The electrostatic contact potential of tubulin 1SA0 and β-tubulin isotypes with docked DAMA-colchicine. The red, blue and white color represents the negative, positive and neutral electrostatic potentials, respectively. The drug DAMA-colchicine bind at the interface of cavity of β-tubulin in tubulin 1SA0 and tubulin isotypes. DAMA-colchicine is shown in green color; oxygen, nitrogen, and sulphur atoms are shown in red, blue, and golden yellow colors respectively. (A) β-tubulin 1SA0 and DAMA-colchicine complex (B) βII tubulin isotype and DAMA-colchicine complex, (C) βIII tubulin isotype and DAMA-colchicine complex (D) βIV tubulin isotype and DAMA-colchicine complex. In βIII tubulin isotype, DAMA-colchicine
prefers different conformation.

**S7 Fig. Radius of gyration for tubulin 1SA0 and β-tubulin isotypes.** Radius of gyration (Rg) values correspond to (A) tubulin 1SA0 (black colour), (B) βII (red colour), (C) βIII (green colour) and (D) βIV (blue colour) of tubulin for 25ns MD simulations. The radius of gyration shows the compactness and stable behavior of β-tubulin structures, during molecular dynamics simulations, for tubulin 1SA0 and three β-tubulin isotypes.

**S8 Fig. Hydrogen bonding after molecular dynamics simulation in tubulin 1SA0 and tubulin isotype.** The residues involved in bonding have been shown in stick with cyan color. Hydrogen bonding between DAMA-colchicine and tubulin residues is shown with black dotted line. Crystal structure of DAMA-colchicine after molecular dynamics simulation is shown in green color. The oxygen, nitrogen and sulphur atoms of DAMA-colchicine has are shown in red, blue and pale yellow color, respectively. (A) Hydrogen bonding between DAMA-colchicine and tubulin 1SA0 amino acids i.e. Glu-198 (2.35Å), Cys-239 (3.12Å), Leu-253 (3.43Å), Asn-256 (2.78Å) and Lys-350 (3.20Å) at binding pocket. (B) Hydrogen bonding between DAMA-colchicine and αβII tubulin isotype amino acids i.e. Cys-239 (2.61Å), Leu-246 (2.31Å), Leu-246 (2.31Å) Asn-258 (3.35Å) and Ala-244 (2.80Å). (C) Hydrogen bonding between DAMA-colchicine and αβIII isotype amino acids i.e. Leu-246 (2.71Å) of β tubulin and Asn-348 (2.78Å) and Pro-222 (2.40Å) of α tubulin in binding pocket. (D) Hydrogen bonding interactions between DAMA-colchicine and αβIV isotype residues i.e. Leu-246 (3.26Å), Leu-253 (2.86Å), Asn-256 (3.40Å) and Lys-350 (3.30Å) of β chain and Ala-180 (2.81Å) of α chain.

**S9 Fig. The electrostatic contact potential of DAMA-colchicine with tubulin 1SA0 and β-tubulin isotypes after molecular dynamics simulation.** Colour scheme is same as shown in S6 Fig. (A) β-tubulin 1SA0 and DAMA-colchicine (B) βII tubulin isotype and DAMA-colchicine (C) βIII tubulin isotype and colchicine and (D) βIV tubulin isotype and DAMA-colchicine. After MD simulation, the drug DAMA-colchicine located inside the binding pocket of β-tubulin in tubulin 1SA0 (A), βII (B) and βIV (D) isotypes whereas in βIII isotypes (C), it expelled from the binding pocket.

**S10 Fig. The conformation of DAMA-colchicine after docking with in-silico mutant structures of αβIII tubulin isotypes.** Color scheme for α-tubulin is tv_orange and β-tubulin is aquamarine. The conformation of DAMA-colchicine (shown in magenta) after docking with in-silico mutant structures of αβIII tubulin isotype (A) αβIII isotype with Ser 239 to Cys mutation, (B) αβIII isotype with Thr 315 to Ala, (C) αβIII isotype with Val 351 to Thr, (D) αβIII isotype with Ser 239-Cys, Thr315-Ala and Val351-Thr. The binding pose of DAMA-colchicine in crystal structure is shown in green.

**S1 Movie.** MD simulation movie of tubulin 1SA0 and DAMA-colchicine.

**S2 Movie.** MD simulation movie of αβII tubulin isotype and DAMA-colchicine.

**S3 Movie.** MD simulation movie of αβIII tubulin isotype and DAMA-colchicine.
S4 Movie. MD simulation movie of αβIV tubulin isotype and DAMA-colchicine. (MPG)

S1 Text. (A) Quality of Homology models of tubulin isotypes. (B) Experimentally measured binding energies of colchicine for bovine αβII, αβIII and αβIV tubulin isotypes. (C) Experimentally measured binding energies of Desacetamidocolchicine (DAAC), a fast binding analogue of colchicine for bovine αβII, αβIII and αβIV tubulin isotypes. (D) Molecular modeling and docking study of in-silico mutant structures of αβIII tubulin isotypes and DAMA-colchicine. (PDF)

Acknowledgments
BVK is thankful to the Indian Institute of Technology Bombay for Post Doctoral Fellowship. DP is thankful to the DAE-SRC fellowship. AK is thankful to the Department of Biotechnology for Innovative Young Biotechnologist Award (Grant Number BT/06/IYBA/2012), New Delhi, India.

Author Contributions
Conceived and designed the experiments: AK DP. Performed the experiments: BVK AB. Analyzed the data: AK DP BVK AB. Contributed reagents/materials/analysis tools: AK DP. Wrote the paper: AK DP BVK.

References
1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4: 253–265. PMID: 15057285
2. Banerjee A, Luduena RF. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem. 1992; 267: 13335–13339. PMID: 1618835
3. Tseng C-Y, Mane JY, Winter P, Johnson L, Huzil T, Izbicka E, et al. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. Mol Cancer. 2010; 9: 131. doi: 10.1186/1476-4598-9-131 PMID: 20509970
4. Luduemä RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998; 178: 207–275. PMID: 9348671
5. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol. 1988; 4: 687–716. PMID: 3058169
6. Berrieman HK, Lind MJ, Cawkwell L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 2004; 5: 158–164. PMID: 15003198
7. Ludueña RF. Are tubulin isotypes functionally significant. Mol Biol Cell. 1993; 4: 445–457. PMID: 8334301
8. Ma C, Li C, Ganesan L, Oak J, Tsai S, Sept D, et al. Mutations in alpha-tubulin confer dinitroaniline resistance at a cost to microtubule function. Mol Biol Cell. 2007; 18: 4711–20. PMID: 17881728
9. Verdier-Pinard P, Shahabi S, Wang F, Burd B, Xiao H, Goldberg GL, et al. Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry. 2005; 44: 15858–15870. PMID: 16313198
10. Sharma S, Poliks B, Chiauzzi C, Ravindra R, Blanden AR, Bane S. Characterization of the colchicine binding site on avian tubulin isotype betaVI. Biochemistry. 2010; 49: 2932–42. doi: 10.1021/bi100159p PMID: 20178367
11. Santoshi S, Naik PK. Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids. J Comput Aided Mol Des. 2014; 28: 751–763. doi: 10.1007/s10822-014-9756-9 PMID: 24916062
12. Kavalariis M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010; 10: 194–204. doi: 10.1038/nrc2803 PMID: 20147901
13. Zhang Y, Yang H, Liu J, Deng Q, He P, Lin Y, et al. High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncol Lett. 2013; 6: 220–226. PMID: 23946808
14. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997; 100: 1282–1293. PMID: 9276747

15. Jaglin XH, Poirier K, Salour Y, Buhler E, Tian G, Babi-Buisson N, et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet. 2009; 41: 746–752. doi: 10.1038/ng.380 PMID: 19465910

16. Poirier K, Saillour Y, Babi-Buisson N, Jaglin XH, Fallet-Bianco C, Nabbout R, et al. Mutations in the neuronal β-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum Mol Genet. 2010; 19: 4462–4473. doi: 10.1093/hmg/ddq377 PMID: 20829227

17. Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, et al. Human TUBB3 Mutations Perturb Microtubule Dynamics, Kinesin Interactions, and Axon Guidance. Cell. 2010; 140: 74–87. doi: 10.1016/j.cell.2009.12.011 PMID: 20074521

18. Chakraborti S, Chakravarty D, Chatterji BP, Dhar G, Poddar A, et al. Discrimination of ligands with different flexibilities resulting from the plasticity of the binding site in tubulin. Biochemistry. 2012; 51: 7138–7148. PMID: 22891709

19. Banerjee S, Chakrabarti G, Bhattacharyya B. Colchicine binding to tubulin monomers: A mechanistic study. Biochemistry. 1997; 36: 5600–5606. PMID: 9159444

20. Garland DL. Kinetics and mechanism of colchicine binding to tubulin: evidence for ligand-induced conformational change. Biochemistry. 1978; 17: 4266–72. PMID: 708711

21. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insights into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004; 428: 198–202. PMID: 15014504

22. Varzhubetsan LR, Glaizahev D V., Nazaryan KB. Molecular dynamics simulation study of tubulin dimer interaction with cytostatics. Mol Biol. 2012; 46: 316–321.

23. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther. 1991; 51: 377–401. PMID: 1792241

24. Banerjee A, Luduena RF. Kinetics of colchicine binding to purified β-tubulin isotypes from bovine brain. J Biol Chem. 1992; 267: 13335–13339. PMID: 1618835

25. Banerjee a, D’Hoore a, Engelborghs Y. Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV. J Biol Chem. 1994; 269: 10324–9. PMID: 8144613

26. McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res. 2013; 41: W597–600. doi: 10.1093/nar/gkt376 PMID: 23671358

27. Rai A, Gupta TK, Kini S, Kunwar A, Suriola A, Panda D. CXI-benzo-84 reversibly binds to tubulin at colchicine site and induces apoptosis in cancer cells. Biochem Pharmacol. 2013; 86: 378–391. doi: 10.1016/j.bcp.2013.05.024 PMID: 23747346

28. DeLano WL. The PyMOL Molecular Graphics System, Version 1.1. Schrödinger LLC. 2002: Available: http://www.pymol.org.

29. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234: 779–815. PMID: 8254673

30. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography. 1993. pp. 283–291.

31. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993; 2: 1511–1519. PMID: 8401235

32. Bowie JU, Lüthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 1991; 253: 164–170. PMID: 1853201

33. Case D a., Darden T, Cheatham TE, Simmerling C, Wang J, Duke RE, et al. Amber 12 Reference Manual. Univ California, San Fr. 2012; 350.

34. Meagher KL, Redman LT, Carlson HA. Development of polyphosphate parameters for use with the AMBER force field. J Comput Chem. 2003; 24: 1016–1025. PMID: 12759902

35. Aliné N, Nilsson L, Villa A. Magnesium ion-water coordination and exchange in biomolecular simulations. J Chem Theory Comput. 2012; 8: 1493–1502. doi: 10.1021/ct3000734 PMID: 26596759

36. Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30: 2785–2791.

37. Dumortier C, Yan Q, Bane S, Engelborghs Y. Mechanism of tubulin-colchicine recognition: a kinetic study of the binding of the colchicine analogues colchicide and isocolchicine. Biochem J. 1997; 327 (Pt 3): 685–8. PMID: 9581543
38. Tsui V, David A, Case DA. Molecular Dynamics Simulations of Nucleic Acids with a Generalized Born Solvation Model. J Am Chem Soc. 2000; 122: 2489–2498.
39. Jani V, Sonavane UB, Joshi R. REMD and umbrella sampling simulations to probe the energy barrier of the folding pathways of engrafted homeodomain. J Mol Model. 2014; 20.
40. Kleinjung J, Fraternali F. Design and application of implicit solvent models in biomolecular simulations. Current Opinion in Structural Biology. 2014. pp. 126–134. doi: 10.1016/j.sbi.2014.04.003 PMID: 24841242
41. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph. 1996; 14: 33–38. PMID: 8744570
42. Gilson MK, Zhou H-X. Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct. 2007; 36: 21–42. PMID: 17201676
43. Perakyla M, Nordman N. Energetic analysis of binding of progesterone and 5β-androstane-3,17-dione to anti-progesterone antibody DB3 using molecular dynamics and free energy calculations. Protein Eng. 2001; 14: 753–758. PMID: 11739893
44. Liao S-Y, Mo G-Q, Chen J-C, Zheng K-C. Exploration of the binding mode between (-)-zampanolide and tubulin using docking and molecular dynamics simulation. J Mol Model. 2014; 20: 2070. doi: 10.1007/s00894-014-2070-6 PMID: 24478043
45. Natarajan K, Senapati S. Understanding the basis of drug resistance of the mutants of 6β-tubulin dimer via molecular dynamics simulations. PLoS One. 2012; 7: e42351. doi: 10.1371/journal.pone.0042351 PMID: 22879949
46. Ge Y, Wu J, Xia Y, Yang M, Xiao J, Yu J. Molecular dynamics simulation of the complex PBP-2x with drug cefuroxime to explore the drug resistance mechanism of Streptococcus suis R61. PLoS One. 2012; 7: e35941. doi: 10.1371/journal.pone.0035941 PMID: 22563422
47. Karthick V, Ramanathan K. Insight into the Oseltamivir Resistance R292K Mutation in H5N1 Influenza Virus: A Molecular Docking and Molecular Dynamics Approach. Cell Biochem Biophys. 2014; 68: 291–299. doi: 10.1007/s12013-013-9709-2 PMID: 23794010
48. Luduena RF, Roach MC. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther. 1991; 49: 133–152. PMID: 1852786
49. Bai RL, Lin CM, Nguyen NY, Liu TY, Hamel E. Identification of the cysteine residue of beta-tubulin alkylated by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography. Biochemistry. 1989; 28: 5606–5612. PMID: 2775724